Methylation of STK11 promoter is a risk factor for tumor stage and survival in clear cell renal cell carcinoma

Zheng,Fufu; Yuan,Xiaoxu; Chen,Enjing; Ye,Yunlin; Li,Xiaofei; Dai,Yuping

doi:10.3892/ol.2017.6534

Methylation of STK11 promoter is a risk factor for tumor stage and survival in clear cell renal cell carcinoma

Authors:
- Fufu Zheng
- Xiaoxu Yuan
- Enjing Chen
- Yunlin Ye
- Xiaofei Li
- Yuping Dai
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong 529030, P.R. China, Department of Urology, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: July 7, 2017 https://doi.org/10.3892/ol.2017.6534
Pages: 3065-3070

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inactivation of tumor suppressor gene serine‑threonine kinase 11 (STK11) in clear cell renal cell carcinoma (ccRCC) has been demonstrated; however, the mechanism of this inactivation remains to be investigated. To investigate whether epigenetic alteration plays a role in the inactivation of STK11 in RCC, the present study aimed to investigate the methylation status of the STK11 promoter and its association with tumor stage and survival in ccRCC patients. Paraffin‑embedded specimens were obtained from 42 ccRCC patients. The specimens were analyzed for the methylation status of the STK11 promoter CpG island using methylation‑specific polymerase chain reaction. Survival, tumor‑node‑metastasis (TNM)/American Joint Committee on Cancer (AJCC) stages, and hematological parameters were compared between patients with unmethylated (U), partially methylated (P) and methylated (M) STK11 promoter. Among the 42 patients, there were 12 (28.6%), 18 (42.9%) and 12 (28.6%) patients in the M, P and U groups, respectively. The methylation status of the STK11 promoter was associated with T, N and AJCC stages in RCC. Survival analysis showed that the M group had a significantly shorter survival time compared with the P and U groups. These findings suggested that methylation of the STK11 promoter in RCC is a not rare event, and it may have an important role in the pathogenesis of RCC and be a risk factor for the prognosis of RCC.

View Figures

View References

1	McLaughlin JK, Lipworth L and Tarone RE: Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 33:527–533. 2006. View Article : Google Scholar : PubMed/NCBI
2	Qin C, Sun LJ, Cui L, Cao Q, Zhu J, Li P, Zhang GM, Mao X, Shao PF, Wang ML, et al: Application of the revised tumour node metastasis (TNM) staging system of clear cell renal cell carcinoma in eastern China: Advantages and limitations. Asian J Androl. 15:550–557. 2013. View Article : Google Scholar : PubMed/NCBI
3	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
4	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W and Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 18:38–43. 1998. View Article : Google Scholar : PubMed/NCBI
6	Zhao RX and Xu ZX: Targeting the LKB1 tumor suppressor. Curr Drug Targets. 15:32–52. 2014. View Article : Google Scholar : PubMed/NCBI
7	Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62:3659–3662. 2002.PubMed/NCBI
8	Kim CJ, Cho YG, Park JY, Kim TY, Lee JH, Kim HS, Lee JW, Song YH, Nam SW, Lee SH, et al: Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer. 40:136–141. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bignell GR, Barfoot R, Seal S, Collins N, Warren W and Stratton MR: Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res. 58:1384–1386. 1998.PubMed/NCBI
10	Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M and Taketo MM: Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res. 62:4549–4553. 2002.PubMed/NCBI
11	Robinson J, Nye E, Stamp G and Silver A: Osteogenic tumours in Lkb1-deficient mice. Exp Mol Pathol. 85:223–226. 2008. View Article : Google Scholar : PubMed/NCBI
12	Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ and Kern SE: Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 154:1835–1840. 1999. View Article : Google Scholar : PubMed/NCBI
13	Avizienyte E, Roth S, Loukola A, Hemminki A, Lothe RA, Stenwig AE, Fosså SD, Salovaara R and Aaltonen LA: Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res. 58:2087–2090. 1998.PubMed/NCBI
14	Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, et al: Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 99:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
15	Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, Salovaara R, Arola J, Bützow R, Husgafvel-Pursiainen K, Kokkola A, et al: LKB1 somatic mutations in sporadic tumors. Am J Pathol. 154:677–681. 1999. View Article : Google Scholar : PubMed/NCBI
16	Yalniz Z, Tigli H, Tigli H, Sanli O, Dalay N and Buyru N: Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma. Tumour Biol. 35:12361–12368. 2014. View Article : Google Scholar : PubMed/NCBI
17	Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, Sahin F, Su GH and Argani P: LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol. 14:146–153. 2006. View Article : Google Scholar : PubMed/NCBI
18	Duivenvoorden WC, Beatty LK, Lhotak S, Hill B, Mak I, Paulin G, Gallino D, Popovic S, Austin RC and Pinthus JH: Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer. 108:327–333. 2013. View Article : Google Scholar : PubMed/NCBI
19	Gan RY and Li HB: Recent progress on liver kinase B1 (LKB1): Expression, regulation, downstream signaling and cancer suppressive function. Int J Mol Sci. 15:16698–16718. 2014. View Article : Google Scholar : PubMed/NCBI
20	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
21	Trojan J, Brieger A, Raedle J, Esteller M and Zeuzem S: 5′-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut. 47:272–276. 2000. View Article : Google Scholar : PubMed/NCBI
22	Lee SM, Choi JE, Na YK, Lee EJ, Lee WK, Choi YY, Yoon GS, Jeon HS, Kim DS and Park JY: Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers. Lung Cancer. 81:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
23	Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA and Herman JG: Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene. 19:164–168. 2000. View Article : Google Scholar : PubMed/NCBI
24	Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH and Goggins M: STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 159:2017–2022. 2001. View Article : Google Scholar : PubMed/NCBI